News

KU, which focuses on generic products, has 18 generic drugs in the market for conditions including attention deficit hyperactivity disorder (ADHD), gastroesophageal reflux disease, hypertension and respiratory disease.

Novartis said it can be used to treat adults with SAA who are either refractory to before immunosuppressive therapy or heavily pretreated and are unsuitable for hematopoietic stem

The advanced infusion technology’s unique expandable tip increases drug delivery into the tumor while protecting healthy tissue. In clinical data recently published in the Journal of Vascular and

It enables preclinical development of Ocata’s proprietary photoreceptor progenitor product for the treatment of retinal degenerative diseases, such as retinitis pigmentosa (RP) and photoreceptor dystrophies. Ocata chief scientific

The acquisition will expand Xerox’s pharmacy solutions portfolio with an offering to help pharmaceutical companies drive product adoption and support patients in minimizing or eliminating financial and reimbursement

HS-110 is the Company’s first product candidate in a series of proprietary ImPACT™ based immunotherapies designed to stimulate patient’s own T-cells to attack cancer. Additionally, as the FDA

VK5211 is an orally available, non-steroidal selective androgen receptor modulator (SARM) being developed to treat patients recovering from non-elective hip fracture surgery. Investigators have dosed the initial subjects

GSK’s two manufacturing facilities in Australia, its opiate product portfolio and inventory will be transferred to Sun Pharma. The acquired business includes analgesics produced from raw materials found

The deal will expand Audentes’ portfolio with the addition of Cardiogen’s lead program for the CASQ2 subtype of catecholaminergic polymorphic ventricular tachycardia (CASQ2-CPVT). No therapies have yet been